When multiple myeloma relapses

RESPOND with KRd – Improvement in quality of life shown from cycle 3 onwards

KRd quality of life data

In the ASPIRE trial, health-related quality of life scores were higher in the KRd vs the Rd group.1 The minimal clinically important difference for between-group differences is 5.0 points, which was met at cycle 2 (5.6 points) and approached at cycle 18 (4.8 points).1


Shown are mean scores for European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status/Quality of Life at each style. Error bars denote standard error

Adapted from Stewart et al.1

Clinical benefits of Kyprolis® in combination with lenalidomide and dexamethasone were associated with significant improvements in quality of life.1,2

Quality of life scores in patients with partial response or better2


Adapted from Stewart et al, 2016.2

*Descriptive P value (one-sided). The KRd group reported improved global health status based on the QLQ-C30 global health status/QoL scale vs Rd over 18 cycles of treatment (P<0.001). The minimal clinically important difference for between-group differences on the QLQ-C30 Global Health Status and Quality of Life scale is 5.0 points, which was met at cycle 12 (5.6 points) and approached at cycle 18 (4.8 points)1
The QLQ-C30 questionnaire includes five functional scales (physical, role, emotional, cognitive and social), three symptom scales (including fatigue, nausea and vomiting, pain and insomnia), a global health status/QoL scale, and six single items

Please read the SmPC for full comprehensive safety information

References

  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Stewart AK et al. J Clin Oncol 2016;34:3921–3930.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis